Zinc finger protein 36 (ZFP36) (ZFP36)

Zinc finger protein 36 (ZFP36), widely known as Tristetraprolin (TTP), is a critical RNA-binding protein that regulates the stability of various messenger RNAs (mRNAs) containing AU-rich elements (AREs) in their 3' untranslated regions. By binding to these elements, ZFP36 recruits the RNA degradation machinery to promote the rapid decay of transcripts encoding potent pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-8. Consequently, ZFP36 serves as a vital endogenous 'brake' on the inflammatory response, and its deficiency or inactivation is linked to the development of chronic inflammatory disorders and various cancers where it acts as a tumor suppressor. In a therapeutic context, ZFP36 is targeted primarily through the modulation of its phosphorylation state; the p38 MAPK/MK2 pathway phosphorylates ZFP36, which inhibits its mRNA-degrading activity and protects it from proteasomal degradation, albeit in an inactive form. Inhibitors of p38 MAPK or MK2 are used experimentally to maintain ZFP36 in its active, unphosphorylated state to suppress inflammation. Additionally, emerging research focuses on small molecules that can transcriptionally upregulate ZFP36 mRNA or stabilize the protein to treat autoimmune diseases and malignancies characterized by the overexpression of ARE-containing oncogenes.

Other names

TristetraprolinTTPG0/G1 switch regulatory protein 24GOS24TIS11NUP475RNF162A

Modulation of ZFP36 activity or expression typically occurs through the inhibition of the p38 MAPK/MK2 signaling pathway, which prevents the phosphorylation-induced inactivation and stabilization of the protein, thereby promoting the degradation of pro-inflammatory mRNAs. Small molecules may also enhance ZFP36 expression to suppress oncogenic or inflammatory transcripts.